An innovative pilot clinical study conducted in Venezuela has demonstrated the efficacy of Cytoreg, a novel ionic therapy developed by Cytorex Biosciences Inc., in the treatment of diabetic foot. The results of this research, published on November 1st in the renowned Journal of Wound Care in the United Kingdom, offer new hope for millions of patients suffering from this complication of diabetes.
Cytorex Biosciences, Inc., headquartered in Florida with a research base in Humble, Texas, is a private biotechnology research and development company at the forefront of innovative therapeutic solutions. Its proprietary technology, Cytoreg, is based on the control of positively and negatively charged ions, using acids to generate therapeutic agents. This versatile technology has the potential to treat a wide range of pathologies, including cancer, autoimmune diseases, neurodegenerative diseases, kidney stones, and infectious diseases.
The study, titled “Efficacy of Cytoreg in the treatment of diabetic foot disease,” presents solid evidence on how this ionic therapy can significantly reduce the risk of amputations and promote ulcer closure in patients with diabetic foot. The research, conducted under a humanitarian compassionate use protocol, involved 10 patients with diabetic foot ulcers.
Key findings of the study include:
Complete wound closure in 4 out of 5 patients who received oral and topical Cytoreg treatment.
Complete wound closure in 2 out of 4 patients who received only oral treatment.
Significant increases in arterial hemoglobin and arterial oxygen partial pressure.
Significant decreases in levels of glycosylated hemoglobin, aspartate aminotransferase, glutamic-pyruvic transaminase, creatine, and urea.
William Jimnez C, CEO of Cytorex Biosciences Inc. and Venezuelan, expressed his enthusiasm for this achievement: “It is an honor and privilege to announce this significant milestone in our mission to improve the health and quality of life of patients. Our research not only offers an innovative therapeutic solution but also has the potential to positively impact the quality of life of many patients. By reducing the number of amputations and promoting ulcer closure, we are contributing to providing hope and recovery opportunities to those who need it most.”
It is important to note that while Cytorex Biosciences Inc. has been recognized for years for its work in developing cancer therapies, the company continues to advance in parallel its therapeutic objectives for brain tumors of the Glioblastoma Multiforme (GBM) type. Jimnez added: “The results obtained in the treatment of diabetic foot are just one of our lines of research. The versatility and efficacy of our ionic therapy allow us to address multiple pathologies without losing sight of our main objective in the field of oncology. This demonstrates the robustness and broad potential of the therapeutic solutions that Cytorex Biosciences Inc. is developing.”
The importance of this innovation becomes evident when considering global statistics on diabetic foot. According to recent data from 2023:
In Latin America, where the study was conducted, the incidence of diabetic foot reaches 14.3% of the diabetic population, with an alarming amputation rate of 12.7 per 100,000 inhabitants.
Globally, incidence rates vary from 8.9% in Africa to 14.3% in Latin America, with amputation rates ranging from 6.2 to 15.4 per 100,000 inhabitants.
“These figures underscore the urgent need for innovative therapies like Cytoreg. Our goal is to drastically reduce these amputation rates and improve the quality of life for millions of patients worldwide,” added Jimnez.
Cytorex has exclusive intellectual property rights over its technology, with pending patents and others in the process of development and preparation, ensuring a leading position in the biotechnology sector. The company represents a unique opportunity in the development of disruptive therapeutic solutions with applications in multiple areas of global health.
“We are excited about the future and committed to continuing to work on developing solutions that transform medical care and improve patients’ lives,” concluded Jimnez. “The results of this study justify conducting an expanded clinical study for the treatment of diabetic foot ulcers with Cytoreg, with the potential to revolutionize treatment in regions where amputation rates are particularly high.”
The medical community, research centers specialized in diabetic foot, and patient organizations are invited to access the complete publication to learn in detail about the results of this pioneering study.
For more information about Cytoreg and other therapeutic projects of Cytorex Biosciences Inc., visit www.cytorex.com. The complete study is available in the October 31, 2024, edition of the Journal of Wound Care. https://www.magonlinelibrary.com/journal/jowc
###
